FINWIRES · TerminalLIVE
FINWIRES

New-Home Buyer Can Save $25,000-Plus Over Decade Amid Lower Operating Costs, Realtor.com Says

By
New-Home Buyer Can Save $25,000-Plus Over Decade Amid Lower Operating Costs, Realtor.com Says

Buyers of new US homes gain a financial advantage during the first decade of ownership, compared with those purchasing existing houses, as energy efficiency and lower maintenance costs help reduce expenses, a report by News Corp's (NWS, NWSA) Realtor.com showed Thursday.

A buyer of an average new home can expect to save $25,335 over the first 10 years of ownership, compared with the purchaser of a 20-year-old house. The savings in a newly constructed home are driven by fewer major repairs and lower energy bills, according to a report by the online real estate portal.

"Homeownership is not a one-time expense, and the ongoing costs of owning a home are where new construction really shines," Realtor.com Senior Economist Joel Berner said.

In 16 of the top 300 US metropolitan areas, the cost savings of purchasing new construction over a decade surpass the pricing gap between the median new-construction listing and the median existing-home listing, according to the report.

"These savings estimates are actually conservative," Berner said. "Builder warranties frequently cover (heating, ventilation, and air conditioning) repairs in the early years, meaning new construction buyers often pay nothing out of pocket."

Massachusetts leads the list with $38,927 in new-construction savings over a 10-year period, as New England's strict building codes and harsh winters outperform Southern markets in energy efficiency gains, the report said.

Considering the mortgage rate buydowns builders have been offering -- which can translate to about $30,000 in savings over a decade -- the total financial advantage of purchasing new homes becomes "even more substantial," Berner said.

Price: $29.97, Change: $-0.72, Percent Change: -2.33%

Related Articles

Cerebras Soars in Nasdaq Debut After Pricing IPO Above Range
US Markets

Cerebras Soars in Nasdaq Debut After Pricing IPO Above Range

Cerebras Systems (CBRS) soared in its public market debut on Thursday after the artificial intelligence chipmaker priced its initial public offering at well above the top end of the projected range.The company set an IPO price of $185 per share for 30 million shares, higher than its prior upgraded range of $150 to $160, Cerebras said late Wednesday. It granted the underwriters an option to buy a maximum of 4.5 million additional shares.The IPO could yield up to $6.38 billion' calculations showed, assuming that underwriters exercise their over-allotment option in full.The stock opened trading on the Nasdaq at $350 on Thursday. Cerebras' share price was most recently up 75% at $324, giving it a market capitalization of more than $70 billion, Yahoo Finance data showed.The offering is anticipated to close on Friday.Cerebras, which competes with companies including Nvidia (NVDA) and Advanced Micro Devices (AMD) in the hardware category, reported 2025 net income of $1.38 per share on revenue of $510 million. That compares with a loss of $9.90 per share and revenue of $290.3 million in 2024.It also competes with cloud service providers such as Amazon (AMZN) Web Services and Microsoft's (MSFT) Azure.Last month, the company said it had raised $2.85 billion in capital over a period of eight months, including a new credit facility for up to $850 million. Cerebras in October 2025 dropped plans to go public.Earlier this year, Cerebras agreed to deploy 750 megawatts of its wafer-scale systems for OpenAI's customers. The deal was valued at more than $20 billion.Price: $315.43, Change: $+130.43, Percent Change: +70.50%

$AMD$AMZN$CBRS$MSFT$NVDA
Equities Rise Intraday Amid Cisco-Led Tech Rally; Trump-Xi Summit in Focus
US Markets

Equities Rise Intraday Amid Cisco-Led Tech Rally; Trump-Xi Summit in Focus

US benchmark equity indexes were higher intraday amid a post-earnings rally in Cisco Systems (CSCO), while markets tracked updates of a high-stakes meeting between President Donald Trump and his Chinese counterpart, Xi Jinping.The Nasdaq Composite was up 0.8% at 26,614 after midday Thursday, while the S&P 500 rose 0.7% to 7,496.6. Both indexes hit fresh record highs in the previous session. The Dow Jones Industrial Average was up 0.7% at 50,054.1 intraday Thursday.Most sectors were in the green, led by technology's 1.6% jump, while materials saw the biggest drop.Cisco shares were up nearly 13%, the biggest gainer on the S&P 500 and the Dow. Late Wednesday, Cisco's fiscal third-quarter results exceeded Wall Street's estimates, while the networking equipment maker announced a restructuring plan that involves thousands of layoffs.Cisco's expanded hyperscaler partnerships are paying dividends for the company, as evidenced by management expectations for a surge in artificial intelligence orders, Morgan Stanley said in a note e-mailed Thursday.Nvidia (NVDA) followed Cisco on the Dow intraday, up 3.6%. About 10 Chinese companies have secured US clearance to purchase Nvidia's H200 AI chip, Reuters reported, citing unnamed sources.Nvidia Chief Executive Jensen Huang is accompanying Trump in his China trip, along with executives of several other major US tech companies.Xi told Huang and CEOs of Apple (AAPL), Tesla (TSLA) and other companies that China will "open wider" to doing business, news outlets reported.Apple shares were down 0.2% intraday, while Tesla rose 0.3%.Boeing (BA) is set to get an order for 200 jets from China, Fox News reported, citing Trump. The US planemaker's shares fell 3.7%, the biggest drop on the Dow.US Treasury yields were mixed intraday, with the 10-year rate down 2.6 basis points at 4.45% and the two-year rate little changed at 3.99%.Xi has pledged not to provide military equipment to Iran, CNN reported, citing Trump.The two leaders agreed that the crucial Strait of Hormuz should remain a free waterway and Iran shouldn't be able to exact payments for the use of shipping lanes, The Wall Street Journal reported, citing a White House readout of the Trump-Xi talks."The market could be pinning too much hope on the US-China talks yielding some positive results on Iran," ING Bank said in a note. "Some hope that China could exert pressure on Iran to reach a deal with the US, to end the war and lead to a resumption of energy flows through the Strait of Hormuz."West Texas Intermediate crude was up 0.4% at $101.37 a barrel intraday, while Brent edged down 0.2% to $105.46.In economic news, US retail sales in April rose for the third straight month, with analysts saying the increase largely reflected higher prices as the war in Iran kept fuel costs elevated."Surprisingly, firm underlying retail sales in April suggest another quarter of moderate consumer spending growth, though higher inflation is bound to take a toll," BMO Capital Markets said in a note. "Inflation pressures are mounting due to the Iran conflict and could take a larger toll on overall spending."Applied Materials (AMAT) is scheduled to report its latest quarterly financial results after the closing bell Thursday.Gold was down 0.4% at $4,687.30 per troy ounce, while silver fell 4.5% to $85.33 per ounce.

$^DJI$^IXIC$^SPX$AAPL$AMAT$BA$CSCO$NVDA$TSLA
Prestige Consumer Healthcare Attributes Soft Results to Low Eye Care Sales, Weak Consumer Backdrop
US Markets

Prestige Consumer Healthcare Attributes Soft Results to Low Eye Care Sales, Weak Consumer Backdrop

Prestige Consumer Healthcare's (PBH) officials said Thursday that weak eye care sales and a difficult consumer backdrop drove disappointing fiscal fourth-quarter results at the consumer healthcare products company.Prestige late Wednesday reported adjusted earnings of $1.23 per share on revenue of $281.6 million. Analysts polled by FactSet expected $1.39 and $293.6 million. The company owns brands including motion sickness treatment Dramamine and Goody's pain relievers.Fourth-quarter revenue was particularly impacted by lower eye care sales, while some international sales were affected by shipping disruptions caused by the Middle East conflict, Chief Financial Officer Christine Sacco said on an earnings call on Thursday, according to a FactSet transcript."The difficult consumer environment persisted into (the fourth quarter) and was further impacted by global conflict," Chief Executive Ron Lombardi told analysts. "While these dynamics led to certain shipment disruptions late in the quarter, we expect to return to organic growth in fiscal 2027 and are well-positioned to manage ongoing macro pressures, including inflation as we have successfully done in the past."Sales for the Clear Eyes brand were below expectations due to delayed shipments and production shutdowns ahead of line updates, Lombardi said on the call.The company's shares plummeted 10% in Thursday trade, bringing their year-to-date decline to nearly 25%.Prestige guided adjusted EPS for the year ending March 2027 in the range of $4.42 to $4.51 on sales between $1.10 billion and $1.12 billion. The current consensus on FactSet is for non-GAAP EPS of $4.74 and revenue of $1.17 billion.Oppenheimer said it expected a below-consensus guide, but "this was worse than we envisioned," according to a note. The brokerage downgraded its rating on the company's stock to perform from outperform and removed the $65 price target.Prestige on Wednesday announced a deal to acquire LaCorium Health for about $150 million in cash. The transaction is expected to close in the second quarter of fiscal 2027.Prestige previously agreed to buy the Breathe Right brand from Foundation Consumer Healthcare."With management now digesting two acquisitions, Clear Eyes execution challenges in recent quarters, higher levels of leverage, and a more uncertain consumer backdrop, we see a weaker outperformance case," Oppenheimer analysts, including Rupesh Parikh, said.Price: $47.49, Change: $-4.33, Percent Change: -8.35%

$PBH